ADPT (Adaptive Biotechnologies) Inventories, Work In Process: $0.0 Mil (As of Mar. 2026)


ADPT Adaptive Biotechnologies Corp ADPT
73 GF Score
Price $19.34
GF Value $10.06
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Adaptive Biotechnologies Inventories, Work In Process?

Adaptive Biotechnologies ADPT +12.34% 73 Inventories, Work In Process is $0.0 Mil as of Mar. 2026. GuruFocus rates ADPT with a GF Score™ of 73/100 and a GF Value™ of $10.06 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Work in process is the part of a manufacturer's inventory that is in the production process and has not yet been completed and transferred to the finished goods inventory. Adaptive Biotechnologies's work in process for the quarter that ended in Mar. 2026 was $0.0 Mil.

Adaptive Biotechnologies Inventories, Work In Process Historical Data

* Premium members only.

The historical data trend for Adaptive Biotechnologies's Inventories, Work In Process can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adaptive Biotechnologies Inventories, Work In Process Chart

Adaptive Biotechnologies Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Work In Process
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

Adaptive Biotechnologies Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventories, Work In Process Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ADPT
73GF Score
Adaptive Biotechnologies Corp ADPT
Inventories, Work In Process is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Adaptive Biotechnologies Inventories, Work In Process Calculation

That part of a manufacturer's inventory that is in the production process and has not yet been completed and transferred to the finished goods inventory. This account contains the cost of the direct material, direct labor, and factory overhead placed into the products on the factory floor. A manufacturer must disclose in its financial statements the cost of its work-in-process as well as the cost of finished goods and materials on hand.

What does a Inventories, Work In Process of $0.0 Mil mean?
Adaptive Biotechnologies (ADPT) has a Inventories, Work In Process of $0.0 Mil as of Mar. 2026. Work in progress is the portion of inventory containing goods that are unfinished. View historical data on Adaptive Biotechnologies and its competitors.
Is Adaptive Biotechnologies' Inventories, Work In Process too high?
Adaptive Biotechnologies' current Inventories, Work In Process is $0.0 Mil. Overall, Adaptive Biotechnologies has a GF Score™ of 73/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Adaptive Biotechnologies' Inventories, Work In Process compare to GRAL and WGS?
Adaptive Biotechnologies' Inventories, Work In Process of $0.0 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Work In Process for a Medical Diagnostics & Research company?
A good Inventories, Work In Process depends on the Medical Diagnostics & Research industry context. However, Inventories, Work In Process should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Work In Process mean?
A high Inventories, Work In Process can signal that a stock is expensive relative to its fundamentals. Work in progress is the portion of inventory containing goods that are unfinished. View historical data on Adaptive Biotechnologies and its competitors. Adaptive Biotechnologies's current Inventories, Work In Process is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adaptive Biotechnologies stock overvalued right now?
Based on GuruFocus' analysis, Adaptive Biotechnologies (ADPT) is currently considered Significantly Overvalued. The stock's GF Value™ is $10.06, compared to a current price of $19.34 — trading 92.2% above its estimated fair value. The current Inventories, Work In Process is $0.0 Mil. Adaptive Biotechnologies' overall GF Score™ is 73/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Work In Process calculated?
Inventories, Work In Process is calculated from a company's financial statements. For Adaptive Biotechnologies (ADPT), the current Inventories, Work In Process is $0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Adaptive Biotechnologies (ADPT) Overvalued in 2026?

Based on GuruFocus' analysis, Adaptive Biotechnologies stock appears to be overvalued. The current stock price of $19.34 is trading 92.2% above its estimated GF Value™ of $10.06. GuruFocus considers Adaptive Biotechnologies to be Significantly Overvalued.

Key valuation signals for ADPT:

  • Inventories, Work In Process: $0.0 Mil
  • GF Value™: $10.06 vs. price of $19.34 (92.2% above fair value)
  • GF Score™: 73/100 with 3 warning signs

No single metric tells the full story. See the ADPT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Adaptive Biotechnologies Business Description

Other Exchanges 1HM:Germany
Address 1165 Eastlake Avenue East, Seattle, WA, USA, 98109
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
73GF Score

Get the complete analysis for ADPT

Inventories, Work In Process is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$19.34
Price
$10.06
GF Value